Pathological prognostic factors in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 31, Issue 3, 1999, Pages 209-223

  Elston, Christopher W ^a   Ellis, Ian O ^a   Pinder, Sarah E ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HORMONE RECEPTOR; INTEGRIN; MUCIN; ONCOPROTEIN; STEROID RECEPTOR; TUMOR MARKER; UVOMORULIN;

ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; HUMAN; LYMPH NODE METASTASIS; PROGNOSIS; REVIEW; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS;

EID: 0032856209     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00034-7     Document Type: Review

References (175)

1. Nyström L., Rutqvist L.E., Wall S. et al. Breast cancer screening with mammography; overview of Swedish randomised trials. Lancet. 341:1993;973-978.
2. Ellis I.O., Galea M.H., Locker A. et al. Early experience in breast cancer screening: Emphasis on development of protocols for triple assessment. Breast. 2:1993;148-153.
3. Rajakariar R., Walker R.A. Pathological and biological features of mammographically detected invasive breast carcinomas. Br. J. Cancer. 71:1995;150-154.
4. Clark G.M. Integrating prognostic factors. Br. Cancer Res. Treat. 22:1992;187-191.
5. Galea M.H., Blamey R.W., Elston C.W. et al. The Nottingham Prognostic Index in primary breast cancer. Br. Cancer Res. Treat. 22:1992;207-219.
6. Clark G.M. Do we really need prognostic factors for breast cancer? Br. Cancer Res. Treat. 30:1994;117-126.
7. Systemic treatment of early breast cancer by hormonal, cytotoxic or immunotherapy. Lancet. 339:1992;1-15.
8. Robertson J.F.R., Bates K., Pearson D. et al. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br. J. Cancer. 65:1992;727-730.
9. Robertson J.F.R., Ellis I.O., Pearson D. et al. Biological factors of prognostic significance in locally advanced breast cancer. Br. Cancer Res. Treat. 29:1994;259-264.
10. National Co-ordinating Group for Breast Screening Pathology. Pathology Reporting in Breast Screening Pathology. 2nd ed. NHSBSP Publications no. 3, 1995.
11. Elston C.W., Ellis I.O. , Editors. Systemic Pathology. The Breast. 3rd ed. 1998;Churchill Livingstone, London.
12. Ellis I.O., Elston C.W. et al. Diagnostic techniques and examination of pathological specimens. Elston C.W., Ellis I.O. Systemic Pathology. The Breast. 3rd ed. 1998;21-46 Churchill Livingstone, London.
13. Pain J.A., Ebbs S., Henn R.P.A. et al. Assessment of breast cancer size: a comparison of methods. Eur. J. Surg. Oncol. 18:1992;44-48.
14. Carter G.L., Allen C., Henson D.E. Relation of tumour size, lymph node status, and survival in 24 740 breast cancer cases. Cancer. 63:1989;181-187.
15. Elston C.W., Gresham G.A., Rao G.S. et al. The Cancer Research Campaign (Kings/Cambridge) trial for early breast cancer - pathological aspects. Br. J. Cancer. 45:1982;655-669.
16. Fisher E.R., Sass R., Fisher B. et al. Pathologic findings from the National Surgical Adjuvant Project for breast cancer (protocol no 4). Discrimination for tenth year treatment failure. Cancer. 53:1984;712-723.
17. Neville A.M., Bettelheim R., Gelber R.D. et al. Predicting treatment responsiveness and prognosis in node-negative breast cancer. J. Clin. Oncol. 10:1992;696-705.
18. Hartman W.H. Minimal breast cancer: an update. Cancer. 53:1984;681-684.
19. Bedwani R., Vana J., Rosner D. et al. Management and survival of female patients with'minimal' breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons. Cancer. 47:1981;2769-2778.
20. Rosen P.P., Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1NOMO-T1N1MO). Assessment of 644 patients with median follow-up of 19 years. Surg. Clin. North Am. 70:1990;937-962.
21. Beahrs O.H., Shapiro S., Smart C. et al. Summary report of the Working Group to review the National Cancer Institute - American Cancer Society Breast Cancer Demonstration Detection Projects. J. Nat. Cancer Inst. 62:1979;641-709.
22. Gibbs N.M. Comparative study of the histopathology of breast cancer in a screened and unscreened population investigated by mammography. Histopathology. 9:1985;1307-1318.
23. Tabar L., Duffy S.W., Krusemo U.B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur. J. Cancer Clin. Oncol. 23:1987;959-962.
24. Frisell J., Eklund G., Hellström L., Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Br. Cancer Res. Treat. 17:1987;219-225.
25. Anderson T.J., Lamb J., Donnan P. et al. Comparative pathology of breast cancer in a randomised trial of screening. Br. J. Cancer. 64:1991;108-113.
26. Royal College of Radiologists. Quality Assurance Guidelines for Radiologists. NHSBSP Publications no. 15, 1990.
27. Royal College of Radiologists. Quality Assurance Guidelines for Radiologists. January 1997. NHSBSP Publications no. 15, 1997.
28. European Commission. European Guidelines for Quality Assurance in Mammography Screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities, 1996.
29. von Hansemann D. Ueber assymetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Virchows Arch. (A) Pathol. Anat. 119:1890;299-326.
30. Carstens P.H.B., Greenberg R.A., Francis D., Lyon H. Tubular carcinoma of the breast. A long-term follow-up. Histopathology. 9:1985;271-280.
31. Clayton F. Pure mucinous carcinomas of the breast: morphologic features and prognostic correlates. Human Pathol. 17:1986;34-38.
32. Page D.L., Dixon J.M., Anderson T.J. et al. Invasive cribriform carcinoma of the breast. Histopathology. 7:1983;525-536.
33. Ridolfi R.L., Rosen P.P., Port A. et al. Medullary carcinoma of the breast - a clinicopathologic study with a ten year follow-up. Cancer. 40:1977;1365-1385.
34. Haagensen C.D., Lane N., Lattes R., Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 42:1978;737-767.
35. Fisher E.R., Gregorio R.M., Redmond C. et al. Tubulolobular invasive breast cancer: A variant of lobular invasive cancer. Human Pathol. 8:1977;679-683.
36. Dawson P.J., Ferguson D.J., Karrison T. The pathologic findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 50:1982;2131-2138.
37. Dixon J.M., Page D.L., Anderson T.J. et al. Long-term survivors after breast cancer. Br. J. Surg. 72:1985;445-448.
38. Ellis I.O., Galea M., Broughton N. et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 20:1992;479-489.
39. Pereira H., Pinder S.E., Sibbering D.M. et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology. 27:1995;219-226.
40. Rapin V., Contesso G., Mouriesse H. et al. Medullary breast carcinoma. A re-evaluation of 95 cases of breast carcinoma with inflammatory stroma. Cancer. 61:1988;2503-2510.
41. Lidang Jensen M., Kiaer H., Andersen J. et al. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology. 30:1997;523-532.
42. Fisher E.R., Kenny J.P., Sass R. et al. Medullary carcinoma of the breast revisited. Br. Cancer Res. Treat. 16:1990;215-229.
43. Pedersen L., Zedeler K., Holck S. et al. Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Br. J. Cancer. 63:1991;591-595.
44. Gaffey M.J., Mills S.E., Frierson H.F. et al. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod. Pathol. 8:1995;31-38.
45. Domagala W., Markiewski M., Kubiak R. et al. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch. (A) Pathol. Anat. Histopathol. 423:1993;497-502.
46. Lamovec J., Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J. Surg. Oncol. 48:1991;28-33.
47. Harris M., Howell A., Chrissohou M. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br. J. Cancer. 50:1984;23-30.
48. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases, Lancet 1997;349:1505-1510.
49. Marcus J.N., Watson P., Page D.L. et al. Hereditary breast cancer. Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer. 77:1996;697-709.
50. Lakhani S.R., Jacquemier J., Sloane J.P. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90:1998;1138-1145.
51. Elston C.W. Grading of invasive carcinoma of the breast. Page D.L., Anderson T.J. Diagnostic histopathology of the breast. 1987;300-311 Churchill Livingstone, Edinburgh.
52. Henson D.E., Ries L., Freedman L.S., Carriaga M. Relationship among outcome stage of disease and histologic grade for 22 616 cases of breast cancer. Br. Cancer Res. Treat. 22:1991;207-219.
53. Elston C.W., Ellis I.O., Goulding H., Pinder S.E. Role of pathology in prognosis and management of breast cancer. Elston C.W., Ellis I.O. Systemic Pathology. The Breast. 3rd ed. 1998;385-434 Churchill Livingstone, London.
54. Scarff RW, Torloni H. Histological typing of breast tumours (International histological classification of tumours, no. 2). Geneva: World Health Organization, 1968.
55. Stenqvist B., Westman-Naeser S., Vegelius J. et al. Analysis of reproducibility of subjective grading systems for breast carcinoma. J. Clin. Pathol. 32:1979;929-985.
56. Gilchrist K.W., Kalish L., Gould V.E. et al. Interobserver reproducibility of histopathological features in stage II breast cancer. An ECPG study. Br. Cancer Res. Treat. 5:1985;3-10.
57. Fisher E.R., Redmond C., Fisher B. Histologic grading of breast cancer. Pathol. Annu. 15:1980;239-251.
58. Hopton D.S., Thorogood T., Clayden A.D. et al. Observer variation in histological grading of breast cancer. Eur. J. Surg. Oncol. 15:1989b;21-23.
59. Theissig F., Kunze K.D., Haroske G., Meyer W. Histological grading of breast cancer - interobserver reproducibility and prognostic significance. Pathol. Res. Pract. 186:1990;732-736.
60. Bloom H.J.G., Richardson W.W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer. 11:1957;359-377.
61. Patey D.H., Scarff R.W. The position of histology in the prognosis of carcinoma of the breast. Lancet. 1:1928;801-804.
62. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:1991;403-410.
63. Connolly J.L., Fechner R.E., Kempson R.L. et al. Recommendations for the reporting of breast carcinoma. Human Pathol. 27:1996;220-224.
64. Dalton L.W., Page D.L., Dupont W.D. Histologic grading of breast carcinoma: a reproducibility study. Cancer. 73:1994;2765-2770.
65. Frierson H.F., Wolber R.A., Berean K.W. et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histological grading scheme for infiltrating ductal carcinoma. Am. J. Clin. Pathol. 105:1995;195-198.
66. Robbins P., Pinder S., de Klerk N. et al. Histological grading of breast carcinomas. A study of interobserver agreement. Human Pathol. 26:1995;873-879.
67. Haagensen C.D. Diseases of the Breast. 1986;WB Saunders, Philadelphia.
68. Harris J.R., Lippman M.E., Morrow M., Hellman S. Diseases of the Breast. 1996;Lippincott-Raven, Philadelphia.
69. Barr L.C., Baum M. Time to abandon TNM staging of breast cancer? Lancet. 339:1992;915-917.
70. Yarnold J., Dixon J.M., Greco M. Consensus document on staging for breast cancer. Breast. 3:1994;238-240.
71. Ferguson D.J., Meier P., Karrison T. et al. Staging of breast cancer and survival rates: an assessment based on 50 years of experience with radical mastectomy. J. Am. Med. Assoc. 248:1982;1337-1341.
72. Veronesi U., Galimberti V., Zurrida S. et al. Prognostic significance of number and level of axillary node metastases in breast cancer. Breast. 2:1993;224-228.
73. Handley R.F. Observations and thoughts on carcinoma of the breast. Proc. Roy. Soc. Med. 65:1972;437-444.
74. Cabanes P.A., Salmon R.J., Vilcoq J.R. et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet. 339:1992;1245-1248.
75. O'Dwyer P.J. Axillary dissection in primary breast cancer; the benefits of node clearance warrant reappraisal (editorial). Br. Med. J. 302:1992;360-361.
76. Blamey R.W. Clinical aspects of malignant disease. Elston C.W., Ellis I.O. Systemic Pathology. The Breast. 3rd ed. 1998;501-513 Churchill Livingstone, London.
77. Archer S, Morgan DAL, Sibbering DM, et al. Regional recurrence in stage I and stage II breast cancer: selection of patients at high risk for radiotherapy, Eur. J. Surg. Oncol. 1999 (submitted for publication).
78. Kutianawala M.A., Sayed M., Stotter A. et al. Staging the axilla in breast cancer: an audit of lymph-node retrieval in one UK regional centre. Eur. J. Surg. Oncol. 24:1998;280-282.
79. Steele R.J.C., Forrest A.P.M., Gibson T. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br. J. Surg. 72:1985;368-369.
80. Dixon J.M., Dillon P., Anderson T.J., Chetty U. Axillary sampling in breast cancer: an assessment of its efficacy. Breast. 7:1998;206-208.
81. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer. 39:1977;456-466.
82. Morton D.L., Wen D.-R., Wong J.H. et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch. Surg. 127:1992;392-399.
83. Alex J.C., Weaver D.L., Fairbank J.T. et al. Gamma probe guided lymph node localisation in malignant melanoma. Surg. Oncol. 2:1993;303-308.
84. Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 220:1994;391-401.
85. Giuliano A.E. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine dissection. J. Surg. Oncol. 62:1996;75-77.
86. Albertini J.J., Lyman G.H., Cox C. et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. J. Am. Med. Assoc. 276:1996;1818-1822.
87. Cox C.E., Pendas S., Cox J.M. et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann. Surg. 277:1998;645-653.
88. Veronesi U., Zurrida S., Galimberti V. Consequences of sentinel node in clinical decision making in breast cancer and prospect for future studies. Eur. J. Surg. Oncol. 24:1998;93-95.
89. Dixon M. Sentinel node biopsy in breast cancer (editorial). Br. Med. J. 317:1998;295-296.
90. McMasters K.M., Giuliano A.E., Ross M.I. et al. Sentinel lymph node biopsy for breast cancer - not yet the standard of care. New Engl. J. Med. 339:1998;990-995.
91. McIntosh S.A., Puroshotham A.D. Lymphatic mapping and sentinel node biopsy in breast cancer. Br. J. Surg. 85:1998;1347-1356.
92. Anderson TJ. The challenge of sentinel lymph node biopsy, Histopathology 1999;15:82-4.
93. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet. 335:1990;1565-1568.
94. Mambo N.C., Gallager H.S. Carcinoma of the breast. The prognostic significance of extrandoal extension of axillary disease. Cancer. 39:1977;2280-2285.
95. Cascinelli N., Greco M., Bufalino R. et al. Prognosis of breast cancer with axillary node metastases after surgical treatment only. Eur. J. Cancer Clin. Oncol. 23:1987;795-799.
96. Fisher E.R., Gregorio R.M., Redmond C. et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). III. The significance of extranodal extension of axillary metastases. Am. J. Clin. Pathol. 65:1976;439-444.
97. Donegan W.L., Stine S.B., Samter T.G. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer. 72:1993;778-782.
98. Rosen P.P., Groshen S., Saigo S. et al. Pathological prognostic factors in stage I (TIN0M0) and stage II (TINIM0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J. Clin. Oncol. 7:1989;1239-1251.
99. Bettelheim R., Penman H.G., Thornton-Jones H. et al. Prognostic significance of peritumoral vascular invasion in breast cancer. Br. J. Cancer. 50:1984a;771-777.
100. Örbo A., Stalsberg H., Kunde D. Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics. Cancer. 66:1990;972-977.
101. Pinder S., Ellis I.O., O'Rourke S. et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up. Histopathology. 24:1994;41-47.
102. Rosen P.P. Tumor emboli in intramammary lymphatics in breast carcinoma: Pathologic criteria for diagnosis and clinical significance. Pathol. Annu. 18:1983;215-232.
103. Davis B.W., Gelber R., Goldhirsch A. et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary node metastases. Human Pathol. 16:1985;1212-1218.
104. Roses D.F., Bell D.A., Fotte T.J. et al. Pathologic predictors of recurrence in stage 1 (T1N0M0 and T2N0M0) breast cancer. Am. J. Clin. Pathol. 78:1982;817-820.
105. Locker A.P., Ellis I.O., Morgan D.A.L. et al. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br. J. Surg. 76:1989;890-894.
106. Kemperman H., Borger J., Hart A. et al. Prognostic factors for survival after breast conserving therapy for Stage I and II breast cancer; the role of local recurrence. Eur. J. Cancer. 31A:1995;690-698.
107. O'Rourke S., Galea M.H., Euhus D. et al. An audit of local recurrence after simple mastectomy. Br. J. Surg. 81:1994;386-389.
108. Fisher E.R., Palekar A.S., Gregorio R.M. et al. Pathologic findings from the National Surgical Adjuvant Project for breast cancers (protocol no. 4). IV. Significance of tumour necrosis. Human Pathol. 9:1978b;523-530.
109. Carter D., Elkins R.C., Pipkin R.D. et al. Relationship of necrosis and tumour border to lymph node metastases and 10 year survival in carcinoma of the breast. Am. J. Surg. Pathol. 2:1978;39-46.
110. Gilchrist K.W., Gray R., Fowble B. et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10 year follow-up study of 728 Eastern Cooperative Oncology Group patients. J. Clin. Oncol. 11:1993;1929-1935.
111. Parham D.M., Hagen N., Brown R.A. Morphometric analysis of breast carcinoma: association with survival. J. Clin. Pathol. 41:1988;173-177.
112. Parham D.M., Hagen N., Brown R.A. Simplified method of grading primary carcinomas of the breast. J. Clin. Pathol. 45:1992;517-520.
113. Elston C.W., Ellis I.O. Method for grading breast cancer (letter). J. Clin. Pathol. 46:1993;189-190.
114. Underwood J.C.E. A morphometric analysis of human breast carcinoma. Br. J. Cancer. 26:1972;234-237.
115. Sistrunk W.E., MacCarty W.C. Life expectancy following radical amputation for carcinoma of the breast - a clinical and pathological study of 218 cases. Ann. Surg. 75:1922;61-69.
116. Black R., Prescott R., Bers K. et al. Tumour cellularity, oestrogen receptors and prognosis in breast cancer. Clin. Oncol. 9:1983;311-318.
117. Parfrey N.A., Doyle C.T. Elastosis in benign and malignant breast disease. Human Pathol. 16:1985;674-676.
118. Shivas A.A., Douglas J.G. The prognostic significance of elastosis in breast carcinoma. J. Roy. Coll. Surg. Edinburgh. 17:1972;315-320.
119. Masters J.R., Millis R.R., King R.J.B., Rubens R.D. Elastosis and response to endocrine therapy in human breast cancer. Br. J. Cancer. 39:1979;536-539.
120. Robertson A.J., Brown R.A., Cree I.A. et al. Prognostic value of measurement of elastosis in breast carcinoma. J. Clin. Pathol. 34:1981;738-743.
121. Rasmussen B.B., Pederson B.V., Thorpe S.M., Rose C. Elastosis in relation to prognosis in primary breast carcinoma. Cancer Res. 45:1985;1428-1430.
122. Parker M.G. Nuclear Hormone Receptors. 1991;Academic Press, London.
123. Beatson JT. Treatment of inoperable cases of carcinoma of the mamma; suggestions for a new method of treatment with illustrative cases, Lancet 1896;ii:104-107.
124. Huggins C., Burgenstal B.M. Inhibition of human mammary and prostatic cancer by adrenalectomy. Cancer Res. 12:1952;134-141.
125. Pearson O.H., Ray B.S., Harrold C.C. et al. Hypophysectomy in the treatment of advanced cancer. J. Am. Med. Assoc. 161:1956;17-21.
126. Dresser R. The effect of ovarian irradiation on the bone metastases of cancer of the breast. Am. J. Radiol. 35:1936;384.
127. NIH Consensus Development Conference. Steroid receptors in breast cancer, Cancer 1980;46:2759-2963.
128. Greene G.L., Nolan C., Engler J.P. et al. Monoclonal antibodies to human estrogen receptor. Proc. Natl. Acad. Sci. USA. 77:1980;5115-5119.
129. Jensen E.V., Greene G.L., De Sombre E.R. The estrogen-receptor immunoassay in the prognosis and treatment of breast cancer. Lab. Manager. 24:1986;25-42.
130. King W.J., Greene G.L. Monoclonal antibodies localize oestrogen receptor in nuclei of target cells. Nature. 307:1984;745-747.
131. McCarty Jr K.S., Miller L.S., Cox E.B. et al. Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109:1985;716-721.
132. Pertschuk L.P., Eisenberg K.B., Carter A.C., Feldman J.G. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Cancer. 55:1985;1513-1518.
133. Paterson D.A., Reid C.P., Anderson T.J., Hawkins R.A. Assessment of oestrogen receptor content of breast carcinoma by immunohistochemical techniques on fixed and frozen tissue and by chemical ligand binding assay. J. Clin. Pathol. 43:1990;46-51.
134. Snead D.J.R., Bell J.A., Dixon A.R. et al. Methodology of immunohistochemical detection of oestrogen receptor in human breast carcinoma in formalin fixed paraffin embedded tissue: a comparison with frozen section morphology. Histopathology. 23:1993;233-238.
135. Goulding H., Pinder S., Cannon P. et al. A new method for the assessment of oestrogen receptor status on routine formalin-fixed tissue samples. Human Pathol. 26:1995;291-294.
136. Hawkins R.A., Sangster K., Tesdale A. et al. The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer: correlation with biochemical assay and prediction of response to endocrine therapy. Br. J. Cancer. 58:1988;77-80.
137. Haybittle J.L., Blamey R.W., Elston C.W. et al. A prognostic index in primary breast cancer. Br. J. Cancer. 45:1982;361-366.
138. Ellis I.O., Bell J., Todd J. et al. Evaluation of immunoreactivity with monoclonal antibody NCRC-II in breast carcinoma. Br. J. Cancer. 56:1987;295-299.
139. Devine P.L., McKenzie I.F.C. Mucins: structure, function, and association with malignancy. Bioessays. 14:1992;619-625.
140. Poller D.N., Hutchings C.E., Galea M. et al. p53 protein expression in human breast cancer: relationship to expression of epidermal growth factor, C-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer. 66:1992;583-588.
141. Harris A.L. What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Br. Cancer Res. Treat. 29:1994;1-2.
142. Lovekin C., Ellis I.O., Locker A. et al. C-erbB-2 oncoprotein in primary and advanced breast cancer. Br. J. Cancer. 63:1991;439-443.
143. Barnes D.M., Dublin E.A., Fisher C.J. et al. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Human Pathol. 24:1993;469-476.
144. Walker R.A., Senior P.V., Jones J.L. et al. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. J. Pathol. 158:1989;97-105.
145. Locker A.P., Dowle C.S., Ellis I.O. et al. C-myc oncogene product expression and prognosis in operable breast cancer. Br. J. Cancer. 60:1989;669-672.
146. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9000 patients. Appl. Immunohistochem. 4:1996;106-116.
147. Walker R.A., Camplejohn R.S. DNA Flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. J. Pathol. 150:1986;37-42.
148. Dowle C.S., Owainati A., Robins A. et al. The prognostic significance of the DNA content of human breast cancer. Br. J. Surg. 74:1987;133-136.
149. Pinder S., Wencyk P., Sibbering D.M. et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br. J. Cancer. 71:1995;146-149.
150. Joensuu H., Toikkanen S., Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br. J. Cancer. 71:1995;155-159.
151. O'Donoghue A.E., Poller D.N., Bell J.A. et al. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Br. Cancer Res. Treat. 33:1995;137-145.
152. Gonzalez M.A., Pinder S.E., Wencyk P.M. et al. An immunohistochemical examination of the expression of E-cadherin, α- and β-catenins and α2- and β1-integrins in invasive breast cancer. J. Pathol. 187:1999;523-529.
153. Weidner N., Carroll R.P., Flax J. et al. Tumor angiogenesis correlates with metastasis in invasive prostatic cancer. Am. J. Pathol. 143:1993;401-409.
154. Goulding H., Rashid A.N.F., Robertson J.F.R. et al. Assessment of angiogenesis in breast cancer. An important factor in prognosis? Human Pathol. 26:1995;1196-1200.
155. Fox S.B. Tumour angiogenesis and prognosis. Histopathology. 30:1997;294-301.
156. Hawkins R.A. Prognostic factors: seeking a shaft of light or getting lost in the woods? a personal view from Sherwood Forest. Breast. 2:1993;125-129.
157. Todd J.H., Dowle C., Williams M.R. et al. Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer. 56:1987;489-492.
158. Chevallier B., Mossen V., Dauce J.P. et al. A prognostic score in histological node negative breast cancer. Br. J. Cancer. 61:1990;436-440.
159. Brown J.M., Benson E.A., Jones M. Confirmation of a long-term prognostic index in breast cancer. Breast. 2:1993;144-147.
160. Balslev I., Axelsson C.K., Zedelev K. et al. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Br. Cancer Res. Treat. 32:1994;281-290.
161. Miller W.R., Ellis I.O., Sainsbury J.R.C., Dixon J.M. Prognostic factors. ABC of Breast Diseases. Br. J. Med. 309:1994;1573-1576.
162. Sibbering D.M., Galea M.H., Morgan D.A.L. et al. Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. Eur. J. Cancer. 31:1995;2191-2195.
163. Fisher B., Redmond C., Fisher E.R. et al. Ten year results in a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. New Eng. J. Med. 312:1985;674-681.
164. Williams M.R., Hinton C.P., Todd J.H. et al. The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br. J. Surg. 72:1985;721-723.
165. Morgan D.A.L., Galea M.H., Berridge J. Post mastectomy radiotherapy in patients at high risk of loco-regional recurrence: a randomised trial. Breast. 1:1992;151.
166. van Leeuwen F.E., Benraadt J., Coebergh J.W. et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
167. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer (abstract 376). ASCO. Los Angeles, CA, 1998.
168. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin to firstline chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomised multinational controlled phase III trial (abstract 377). ASCO. Los Angeles, CA, 1998.
169. Pinder S.E., Murray S., Ellis I.O. et al. The importance of histological grade in invasive breast carcinoma and response to chemotherapy. Cancer. 83:1998;1529-1539.
170. Davis B.W., Gelber R.D., Goldhirsch A. et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 58:1986;2662-2670.
171. Contesso G., Mouriesse H., Friedman S. et al. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institut Gustave-Roussy. J. Clin. Oncol. 5:1987;1378-1386.
172. Le Doussal V., Tubiana-Hulin M., Friedman S. et al. Prognostic value of histologic grade nuclear components of Scarff Bloom Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 64:1989;1914-1921.
173. Hopton D.S., Thorogood J., Clayden A.D., Mackinnon D. Histological grading of breast cancer: significance of grade on recurrence and mortality. Eur. J. Surg. Oncol. 15:1989;25-31.
174. Schumacher M., Schmoor C., Sauerbrei W. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Br. Cancer Res. Treat. 25:1993;235-245.
175. Genestie C., Zafrani B., Asselain B. et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both systems. Anticancer Res. 18:1998;571-576.